Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01189 (
beta-endorphin
)
21,003
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Effects of
alpha-melanocyte-stimulating hormone
(
alpha-MSH
),
beta-melanocyte-stimulating hormone
(
beta-MSH
), beta-lipotropin (
beta-LPH
), and
beta-endorphin
(beta-EPH) at concentrations from 10(-9) M up to 10(-6) M on human adipose tissue lipoprotein lipase (LPL) were studied in a cell-free system.
alpha-MSH
and
beta-MSH
did not exert any effect on LPL; no degradation of these peptides in the incubation medium could be detected by HPLC analysis.
beta-LPH
and beta-EPH failed to alter enzyme activity. However, HPLC analysis revealed an unspecific rapid degradation of the peptides due to the activity of tissue proteases. Therefore, the protease inhibitors amastatin, antipain, APMSF, and
TPCK
were tested at concentrations of 10(-5), 10(-4), and 10(-3) M for their efficacy to inhibit degradation. None of the inhibitors was able to substantially reduce proteolysis of
beta-LPH
, as was the case with amastatin, APMSF, and
TPCK
for beta-EPH. However, antipain at 10(-4) M preserved at least 20% of the initial peptide concentration from proteolysis up to 150 min. Antipain caused a decrease in lipoprotein lipase activity (LPLA), which was dependent on concentration. The adverse effect of antipain at concentrations of 10(-4) M on LPL was completely abolished by beta-EPH at a concentration of 10(-6) M.
...
PMID:Proopiomelanocorticotropin (POMC) peptides and lipoprotein lipase activity in vitro. 747 1
